View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Fluids & Electrolytes
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Abstract: Many cancer survivors suffer from chronic pain related to treatment. Pain management in the survivor is similar to chronic noncancer pain, with the important caveat that new or worsening pain must be promptly assessed for malignancy. This article reviews cancer survivorship, identifies common pain problems, and discusses strategies for management.
Cancer survivorship is a growing field, as more people are successfully treated and survive long term.1 However, many survivors must cope with significant long-term or late effects of cancer and cancer treatment, including pain.2 The approach to chronic cancer-related pain (CCRP) builds on strategies similar to that of chronic noncancer pain (CNCP), with the important caveat that any new or changed pain must be promptly and thoroughly evaluated to rule out malignancy as the source.3 While the total number of cancer survivors is increasing, there is an anticipated shortage of oncologists by the year 2020.4 Thus, the long-term follow-up and management of chronic problems in survivors will more commonly be handled in the setting of primary care, and the nurse practitioner (NP) must become familiar with problems unique to this group.5,6
This article reviews issues of cancer survivorship and common chronic pain syndromes encountered in primary care, as well as some management strategies. Pain symptoms that may herald disease recurrence and require urgent evaluation will be discussed. Using a case study, an approach to opioid management for the cancer survivor will be examined.
Ms. J is a 52-year-old Black female with a history of Stage II-b right breast cancer. She underwent a partial mastectomy (lumpectomy) 18 months ago followed by chemotherapy and radiation. She completed treatment 1 year ago and has no current evidence of active cancer. She is on an aromatase inhibitor (AI), letrozole, for 5 years for prevention of breast cancer recurrence.
Ms. J complains of chronic, painful chemotherapy-induced peripheral neuropathy (CIPN) in her hands and feet, which she rates as a pain intensity of 6 on a 0 to 10 scale. She also notes significant arthralgia from the letrozole, 4/10 pain intensity, affecting the shoulders, hips, and knees, as well as a "tightness" in the right chest wall from radiation fibrosis. The pain impacts her quality of life, reduces her overall functionality, and contributes to fatigue. The CIPN is especially bothersome, as the associated pain and numbness in her fingers and hands impact her ability to enjoy her hobby as a sculptor.
During cancer treatment, Ms. J was prescribed opioids for pain. More than a year later, she remains on opioids, and the dose has been slowly escalated due to complaints of worsening pain. She is currently on extended-release morphine 15 mg tablets three times a day. In addition, she takes immediate-release morphine 15 mg tablets (1 to 2)every 4 hours as needed for pain, maximum limit of 4 tablets per day; however, she reports that she is actually taking 6 to 10 tablets per day. Gabapentin was previously tried at a starting dose of 300 mg three times daily, but Ms. J stopped it after 3 days, reporting she was too sleepy and that "it didn't work." She declines to try an antidepressant for CIPN, indicating that she is not depressed. She stopped exercising regularly during cancer treatment and has never restarted.
Ms. J remains unemployed, citing excessive pain and fatigue that prevent her from working. She lives alone, feels isolated, and no longer gets together with her friends.
At her visit to the Women's Primary Care Clinic, Ms. J requested an increased dose of long- and short-acting morphine due to ongoing and worsening pain. What options are available? What additional information is needed?
The National Cancer Institute created the Office of Cancer Survivorship in 1996 to support research into the unique issues and needs of the cancer survivor and their caregivers. This website defines survivorship as beginning at the time of cancer diagnosis and extending through the balance of life.7 However, this broad definition includes people with and without evidence of active malignancy.
When examining the long-term sequelae of cancer and cancer treatment, a more useful description of the cancer survivor refers to those affected by the following8,9:
* Have completed the active antineoplastic phase of their treatment (with the exception of AIs or tamoxifen for prevention of breast cancer recurrence)
* Have no evidence of disease
* Are under cancer surveillance
* The cancer pain syndrome is not related to active disease progression.
Chronic symptoms, such as fatigue and pain, occur frequently after cancer treatment, and may severely impact the survivor's quality of life, function, vocational choices, and leisure activities.10 Coping with these difficult symptoms is sometimes referred to as "the price of survival," reflecting the mixed sentiments of gratefulness for survival while acknowledging the tremendous impact of the symptoms experienced11 (see Cancer survivorship overview).
Reports of chronic pain are common in the cancer survivor and are typically a result of the cancer treatment rather than the disease itself. An analysis of the 2002 National Health Interview Survey in over 30,000 persons found the incidence of pain in cancer survivors was much higher (34%) than controls without a history of cancer (18%).12 The highest prevalence occurs in postthoracotomy (up to 80%), postamputation/phantom limb (50% to 80%), postneck dissection (52%), and breast cancer (63%) patients.9,13
It is important for clinicians to promptly address new complaints of pain in the survivor to determine the cause, rather than taking the more conservative approach used in a patient with no history of cancer. For example, guidelines for assessment and management of acute low back pain (LBP) encourage delayed imaging and reevaluation in 1 month for those with nonspecific symptoms, as this problem is typically a self-limiting condition.14 However, the approach to new-onset LBP in the patient with a history of cancer requires prompt evaluation to rule out a pathologic vertebral compression fracture or emergent conditions, such as epidural spinal cord compression (SCC) from vertebral body metastasis. This is especially true in cancers that are most likely to metastasize to the bone, including prostate, breast, and lung cancer.15 Although rare in the setting of cancer remission or cure,16 SCC may be the first indication of metastatic disease and is associated with a 100% incidence of hemi- or quadriplegia if not diagnosed and treated promptly.17
Signs and symptoms that warrant prompt assessment in the cancer survivor include15,18:
* a new or worsening pain
* pain worse at night or with recumbency
* signs of possible SCC:
- new-onset or worsening back pain (especially thoracic pain), or pain in a band around the torso, pain worse with Valsalva maneuver
- progressive neurologic deficits such as saddle anesthesia (numbness in the S-2 dermatome: perineum, lower buttocks, posterior proximal thighs); sensory changes in the arms or legs; weakness, including a sense of "heaviness" or "clumsiness" of the limbs, or stumbling gait
- bowel or bladder changes (lax anal sphincter with fecal incontinence or overflow urinary incontinence).
* Associated symptoms concerning for malignancy:
- unexplained weight loss more than 10 lb (4.5 kg), night sweats, fevers and chills, enlarging masses, or unusual fatigue.
- additional worrisome symptoms include excessive bruising or bleeding, change in moles or skin, altered bowel function, difficulty swallowing, persistent cough, or hoarseness.
As with any pain problem, the first task is to determine the source of the pain, and, in the survivor, establish that it is not related to active cancer (see CCRP syndromes and treatments in the survivor). The three primary types of pain are as follows19:
* neuropathic (abnormal nerve impulses, commonly from chemotherapy)
* nociceptive/somatic (involving muscles, bone, connective tissue)
* nociceptive/visceral (involving organs, such as liver or pancreas)
Listed below are several pain syndromes commonly seen in the cancer survivor:
* CIPN is a frequently encountered problem in primary care. This manifests as a symmetrical distal sensory neuropathy in a "stocking-glove" distribution. CIPN may be painful (burning, shooting) or nonpainful (numbness). Patients at higher risk for developing CIPN are those with the following20:
- preexisting painful neuropathy from diabetes or other cause
- higher cumulative doses of neurotoxic chemotherapy agents
- combination of multiple neurotoxic agents
- older age.
* Neuropathic pain syndromes associated with surgery include postmastectomy, postthoracotomy, postradical neck, and postamputation pain syndromes.3 The pain usually declines over months to years but may persist for the patient's lifetime. Other less common neuropathic pain syndromes include brachial or lumbosacral plexopathy.
* Myofascial pain syndromes related to cancer treatment are a frequently overlooked source of somatic pain in the survivor. This problem results from tissue scaring and fibrosis caused by radiation or surgery. For example, radiation fibrosis is a significant cause of shoulder dysfunction, limited range of motion, and associated pain in the shoulder and chest wall21; it is observed in persons treated for breast cancer, Hodgkin lymphoma, or head and neck cancers. Interestingly, myofascial problems may develop months or years after completion of treatment.
* Myalgia and arthralgia are common in breast cancer survivors taking AIs (such as letrozole, exemestane, or anastrozole). This therapy is prescribed for 3 to 5 years after completion of treatment to prevent disease recurrence. The high incidence (up to 47%) of AI-associated chronic musculoskeletal pain impacts patient adherence with the plan of care in 20% of patients.22 A comprehensive pain management strategy will encourage long-term adherence to the AI therapy, and, thus, may reduce the risk of breast cancer recurrence.23
* Lymphedema is a common long-term problem for cancer survivors and a source of discomfort in those treated for breast, head and neck, or pelvic tumors.24 This condition responds to manual lymphatic drainage and compression garments.
* Osteoporosis is a concern in cancer survivors. Chemotherapy, surgery, or radiation may induce ovarian failure and menopause in women; androgen-deprivation therapy for biochemical relapse (or metastatic) prostate cancer is a source in men. Osteoporosis increases the risk of painful vertebral compression fractures or other bone fractures, leading to chronic pain.9
* Dyspareunia is a frequent issue due to vaginal dryness, vaginal atrophy, or stricture associated with ovarian failure or radiation therapy.25,26 The clinician should specifically ask about concerns with sexuality, sexual function, and dyspareunia, as patients may not feel comfortable initiating this discussion.
* Radiation-induced visceral pain syndromes include chronic proctitis, cystitis, enteritis, or tenesmus.9
Some survivors may become hypervigilant of their bodily sensations, and present frequently to the clinic with reports of new symptoms, fearful of cancer recurrence.27 Most survivors are aware that pain can be an early sign of cancer recurrence and have been taught to report these symptoms promptly. Emotional distress, depression, anxiety, and fear may contribute significantly to the resulting pain experience.3 An individualized approach to each patient is needed in this setting to determine the proper frequency of radiologic imaging and other surveillance monitoring. Oncologist collaboration is useful to help in making this determination.
In contrast, some survivors may underreport pain problems for the same reason: Fear of cancer recurrence.28 This requires careful questioning by the clinician to obtain an accurate assessment of the situation.
Once the provider is assured that the pain does not represent recurrent disease, a pain management plan can be developed. Management of CCRP is emerging as a new field that builds on strategies more akin to that of CNCP, along with functional restoration using a rehabilitation model.3 The important exception, as noted above, is the requirement to promptly and thoroughly evaluate new pain reports for possible malignancy (see Key points in managing pain in the cancer survivor).
Survivors with chronic pain are encouraged to actively participate in their pain management plan of care and utilize a broad range of therapies.29 These methods include a multimodal approach to pain care with an emphasis on self-activation and nonpharmacologic therapies. Strategies include regular aerobic activity, thermal therapy, and home physical therapy stretching and strengthening exercises. Counseling to address anxiety, depression, coping, and complementary therapies, such as acupuncture, massage, and yoga are additional supportive approaches. In selected patients, interventional modalities may be considered, including nerve blocks, trigger point injections, spinal cord stimulators, or implanted intrathecal pumps.9,30 Medication options include the adjuvant agents: antidepressants, antiepileptic drugs, and topical agents in addition to non-steroidal anti-inflammatory agents and acetaminophen.22 While opioids are utilized in this setting, their use is deemphasized.3
Survivors may express confusion and frustration as they note a shift away from opioids as the primary approach to management of pain. During acute cancer treatment, the drug of choice for moderate-to-severe pain is an opioid, and reports of increased pain are typically addressed by increasing the opioid dose, with adjuvant agents added as appropriate.31,32 However, while opioids are utilized for the survivor with chronic pain, the focus changes to one of stabilizing and reducing the total opioid dose, rather than providing ever-escalating dosages. In this way, the approach to chronic opioid therapy (COT) in a survivor builds on the strategies utilized for the management of CNCP.33 It is important for the primary care provider to understand that there is no "mandate" to prescribe opioids to the survivor with CCRP.34,35 Opioid therapy is a useful tool but is not the only treatment strategy available.
It is essential that the clinician carefully explains the rationale for changing the model of care from one of primarily opioids with escalation-upon-demand to one of multimodal therapies as noted above. Clinicians should explain that emerging evidence does not support the use of chronic opioids as the sole therapy for chronic pain due to concerns regarding long-term adverse reactions, such as hypogonadism.34 The patient's fears and concerns must be addressed, questions answered, and plan of care negotiated. This discussion may take several visits to accomplish in order to reach a plan of care that is mutually agreeable.
There are no FDA-approved medications specifically for CCRP. Treatment of CIPN has typically followed recommendations for painful diabetic peripheral neuropathy (DPN), including the FDA-approved drugs pregabalin and duloxetine; gabapentin is used off-label for DPN. A recent study showed duloxetine to be effective in CIPN.36 Unfortunately, gabapentin for management of CIPN pain has not been shown to be effective.37 Use of duloxetine, however, appears to be showing promise in CIPN.36 Patient education when using antidepressants or antiepileptic drugs includes the need to titrate doses and a delay until pain relief is achieved.19 For example, duloxetine takes 1 to 2 weeks to start noticing a pain-relieving effect, as does gabapentin, if started at lower doses.38 Pregabalin is an exception, with pain relief noted in as little as 2 days.
Acetaminophen may improve mild-to-moderate pain for some patients. Review of hepatic and renal function is necessary, with dose reduction, or discontinuation, for abnormal values or in the setting of excessive alcohol intake. Recent evidence suggests that chronic use of acetaminophen should be limited to 3,250 mg per day or less, especially in older patients.39,40 To avoid inadvertent overdose, which could lead to liver injury, the provider should carefully assess for acetaminophen-containing over-the-counter medicines (such as products for migraine headaches, cold and flu), or prescribed combination products (such as hydrocodone/acetaminophen).41
Nonsteroidal anti-inflammatory drugs (NSAIDs) may aid in management of myofascial and skeletal pain but should be administered cautiously when given on a chronic basis. These drugs are generally contraindicated in the patient on anticoagulant therapy, or with a history of gastroduodenal bleeding, and must be dose-reduced or avoided in those with chronic kidney disease.42,43 The benefit-to-burden ratio must be carefully weighed when considering chronic use of NSAIDs in the patient with hypertension or heart failure due to the potential exacerbation of these conditions. NSAIDs should be avoided in older adults due to age-related renal impairment and the potential risk of inducing renal failure.40
Topical NSAIDs may be an option for those with musculoskeletal pain. Diclofenac epolamine patch (FDA-approved for acute pain from minor sprains and strains) delivers medication to the site of pain with minimal systemic absorption.44 Other topical agents that may aid in management of postsurgical pain syndromes include lidocaine 5% topical patch (FDA-approved for post-herpetic neuralgia) or capsaicin cream (FDA-approved for musculoskeletal pain), which are applied directly to the site of pain.45
As with CNCP, the role of psychosocial distress in escalating the survivor's pain experience must be explored. After conducting a thorough evaluation, the survivor must be reassured that the chronic pain is indeed "real," that their report is believed, but the source is from effects of cancer treatment, and not from cancer recurrence. Helping the patient understand the contribution of psychosocial stressors to the pain experience is essential and may aid in their acceptance of treatment for depression, anxiety, and posttraumatic stress disorder that may contribute to hypervigilance. A focus on regular exercise, and utilization of mindfulness techniques, such as imagery, relaxation, and breathing practices, will improve the sense of overall well-being, and may decrease the need for pain medications.
After obtaining a detailed history and physical exam, including review of recent imaging studies, the NP discovers that Ms. J has struggled with anxiety and depression in the past, as well as a remote history of alcohol abuse and recreational drug use (including cannabis, cocaine, methamphetamine, but no injected drugs), and has several family members with similar struggles. Ms. J has been clean and sober for 8 years but admits she recently has felt tempted to start drinking alcohol again, although she has not. To specific questioning, she denies using recreational drugs, obtaining additional opioids on the street, or sharing or selling her opioid prescriptions to others. Ms. J reports she is feeling more anxious and out-of-control lately due to worries that the breast cancer will return in addition to financial and personal relationship issues. With careful questioning, the NP helps Ms. J understand that she has been using opioids to cope with excessive anxiety rather than pain control. "The morphine just helps me to chill out, you know? It helps me not to worry so much."
Plan of care:
1. The provider reassures Ms. J that there are no findings indicating cancer recurrence and reviews the plan for ongoing close monitoring that will be provided. She normalizes the feelings of fear and uncertainty about cancer recurrence and encourages Ms. J to consider joining a breast cancer survivor support group to learn new coping strategies for the anxiety. This group also offers a free weekly workout program with a certified trainer, which will help reduce the anxiety, excess weight, and chronic pain.
2. She diagnoses Ms. J with anxiety and depression and discusses strategies for management, including counseling, regular aerobic exercise, and pharmacologic management. Patient education is provided regarding the proper utilization of opioids to treat pain but emphasizes that escalating opioid use is not appropriate for coping with anxiety, stress, and uncertainty. She relates that this is called "chemical coping" (or "self-medicating") and points out that it is not beneficial to Ms. J in the long run.46
3. A multimodal pain management strategy is discussed in detail. A plan of care is initiated that includes duloxetine 30 mg daily to treat anxiety, depression, and painful neuropathy. An exercise program, which includes aerobic and strengthening workouts, is recommended, as it will aid the AI-induced myalgia and arthralgia. Future medication considerations for pain include the addition of acetaminophen and/or naproxen for myalgia and arthralgia, and possibly a trial of pregabalin. Future training in mindfulness therapies and an acupuncture trial are also discussed.
4. Ms. J agrees to reduce the opioid use back down to the current prescribed doses but expresses concern about her ability to do this. The provider institutes 2-week prescription quantities for a period of time to help Ms. J maintain the agreed-upon plan and dosing limits. The NP gives Ms. J a written Controlled Substances Agreement and Informed Consent and asks her to review it at home. This form includes patient and provider responsibilities and clinic policies related to opioid prescriptions (for example, call 3 business days in advance for renewals and no early renewals for lost prescriptions). Additionally, the informed consent details the risks and benefits of treatment, management of medication adverse reactions, and issues that warrant a phone call. The provider points out that the agreement includes consent for occasional urine drug screens.
5. A follow-up visit is scheduled in 2 weeks to answer questions, review, and sign the agreement. She reassures Ms. J that use of the opioid consent is standard practice in the clinic for those receiving COT for chronic pain and is not meant to be punitive in nature. Rather, it is a way to communicate expectations clearly.
Management of chronic pain in the cancer survivor is an emerging field, with growing numbers of patients who, although free from disease, continue to suffer from treatment-related pain. Clinicians, especially those in the fields of primary care and women's health, should expect to see more survivors in their practice. Research is needed to direct providers in the best approach for treatment of CCRP, especially CIPN. Until more data are available, pain management strategies for the survivor follow the general guidelines for the patient with CNCP. The one major departure is that any new or worsening pain problem must be promptly assessed for cancer recurrence as the source. The NP is uniquely situated to provide holistic care to the cancer survivor. This includes addressing the physical as well as the psychosocial impact of malignancy and assisting the survivor in his or her journey from illness to wellness.
* For the purposes of this article, a cancer survivor is someone who has no evidence of disease, is not receiving active antineoplastic treatment, and is under cancer surveillance only.
The number of cancer survivors is increasing:
* The overall prevalence of long-term cancer survivors is increasing due to improved therapies. In addition, population growth and aging contribute to rising global incidence of new cancer diagnosis.
The three most common sites for those living with a history of cancer in 2012 include:
* Men: prostate cancer (43%), colorectal cancer (9%), and melanoma (7%)
* Women: breast (41%), uterine (8%), and colorectal (8%) cancer
Physical symptoms in cancer survivors include:
* chronic pain problems
* cognitive problems
* functional limitations
* alterations in sexuality and fertility
Psychosocial impact of cancer survivorship:
* depression and anxiety
* pervasive fear of cancer recurrence
* feelings of uncertainty and heightened sense of vulnerability
* employment challenges
* posttraumatic growth: positive feelings of gratitude, personal growth, improved self-esteem
Many major cancer centers have clinics that specifically address the unique needs of the survivor. For example:
* Fred Hutchison Cancer Research Center/Seattle Cancer Care Alliance
* MD Anderson Cancer Center
* Memorial Sloan Kettering Cancer Center:
Treatment Care Plans (TCP):
The Institute of Medicine recommends that all patients be given a written TCP at the completion of therapy. The TCP provides a concise summary of all antineoplastic treatments received, including chemotherapy cumulative doses, radiation portal and dose, and surgeries. Ideally, the TCP includes information on possible long-term and late effects of treatment and recommendations for the frequency of ongoing cancer screening. Survivorship clinics (see above) provide survivors with detailed TCPs, or utilize the website below.
* Create your own Survivorship Treatment Care: Patients and providers may create a TCP in English or Spanish at http://www.livestrongcareplan.org/
* LiveStrong: The Lance Armstrong Foundation (http://www.LiveStrong.org)
* National Cancer Survivorship Resource Center/American Cancer Society (http://www.cancer.org/treatment/survivorshipduringandaftertreatment/nationalcanc
* National Cancer Institute Office of Cancer Survivorship (http://dccps.nci.nih.gov/ocs/)
1. "Be certain of the source of pain!"
* Investigate all new, changing, or worsening pain problems to rule out cancer recurrence.
2. Reassure and redirect the patient
* Patients who have experienced cancer are understandably fearful that pain is from a cancer source. Once cancer recurrence has been eliminated, provide education and reassurance. Redirect the patient to optimizing overall health with exercise, proper diet, and balanced living.
* Address anxiety and depression, as these issues impact the pain experience.
* Provide reassurance of ongoing coordination with the oncologist to regularly monitor for cancer recurrence.
3. Utilize an individualized multimodal approach to pain management*
* Antidepressants, antiepileptic drugs, or topical agents for neuropathic pain.
* Acetaminophen, NSAIDs (such as celecoxib, naproxen, or ibuprofen), or topical agents for somatic nociceptive pain sources. (See text for precautions.)
- Nonpharmacologic therapies are helpful for all types of pain, especially myofascial pain. These include physical or occupational therapy, aerobic and strengthening exercises, thermal (hot or cold) compresses, massage, and transcutaneous electrical nerve stimulation (TENS) therapy. TENS is a method of pain relief that uses a portable battery-operated unit that provides mild electrical stimulation to "distract" the brain from sensing pain input.
* Complementary modalities, such as acupuncture, yoga, aromatherapy, and naturopathic medicine.
* Sleep hygiene is essential, as impaired sleep may exacerbate myofascial pain, anxiety, and depression.
4. Opioids: utilize a chronic pain model instead of an acute cancer pain model for the disease-free cancer survivor with long-term chronic pain.
* Opioids may be appropriate if other modalities are not fully effective as third-line therapy.
* The focus is on stable, non-escalating doses, with a goal to reduce the opioid dose to the lowest therapeutic level.
* Avoid repeated dose escalations if there is no progressive pathology. If opioid tolerance is suspected, consider rotation to a different opioid.
* As in chronic, noncancer pain, use of a written Controlled Substances Provider-Patient Agreement and Informed Consent document is recommended. Screening for risk of opioid misuse, including psychosocial issues that may impact opioid use patterns, is essential. Consider urine drug testing to assess for the presence or absence of prescribed, nonprescribed, or street drugs.
* For more information, see the American Pain Society Opioid Treatment Guidelines.35
5. Never become complacent about the survivor's complaints of pain. Always consider cancer recurrence in the differential diagnosis.
* Note: There are no FDA-approved drugs specifically for chronic cancer related pain or chemotherapy induced peripheral neuropathy.
1. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220-241. [Context Link]
2. van den Beuken-van Everdingen M. Chronic pain in cancer survivors: a growing issue. J Pain Palliat Care Pharmacother. 2012;26(4):385-387. [Context Link]
3. Burton AW, Fanciullo GJ, Beasley RD, Fisch MJ. Chronic pain in the cancer survivor: a new frontier. Pain Med. 2007;8(2):189-198. [Context Link]
4. American Society of Clinical Oncology. 2008-2013 Workforce Strategic Plan to Ensure Continuing Access to Quality Cancer Care. 2008. http://www.asco.org/advocacy-practice/workforce-initiatives. [Context Link]
5. Hudson SV, Miller SM, Hemler J, et al. Adult cancer survivors discuss follow-up in primary care:'not what I want, but maybe what I need'. Ann Fam Med. 2012;10(5):418-427. [Context Link]
6. Burstein HJ, Winer EP. Primary care for survivors of breast cancer. N Engl J Med. 2000;343(15):1086-1094. [Context Link]
7. Office of Cancer Survivorship. Survivorship Definitions. 2011. http://dccps.nci.nih.gov/ocs/definitions.html. [Context Link]
8. Feuerstein M. Defining cancer survivorship. J Cancer Surviv. 2007;1(1):5-7. [Context Link]
9. Polomano R, Ashburn M, Farrar J. Pain syndromes in cancer survivors. In: Bruera ED, Portenoy, RK, eds. Cancer Pain: Assessment and Management. 2nd ed. New York: Cambridge University Press; 2010:145-163. [Context Link]
10. Harrington CB, Hansen JA, Moskowitz M, Todd BL, Feuerstein M. It's not over when it's over: long-term symptoms in cancer survivors-a systematic review. Int J Psychiatry Med. 2010;40(2):163-181. [Context Link]
11. Hewitt ME, Greenfield S, Stovall E. From Cancer Patient to Cancer Survivor: Lost in Transition. National Academy Press; 2006. [Context Link]
12. Mao JJ, Armstrong K, Bowman MA, Xie SX, Kadakia R, Farrar JT. Symptom burden among cancer survivors: impact of age and comorbidity. J Am Board Fam Med. 2007;20(5):434-443. [Context Link]
13. Sun V, Borneman T, Piper B, Koczywas M, Ferrell B. Barriers to pain assessment and management in cancer survivorship. J Cancer Surviv. 2008;2(1):65-71. [Context Link]
14. Chou R, Qaseem A, Snow V, et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med. 2007;147(7):478-491. [Context Link]
15. Prasad D, Schiff D. Malignant spinal-cord compression. Lancet Oncol. 2005;6(1):15-24. [Context Link]
16. Cole JS, Patchell RA. Metastatic epidural spinal cord compression. Lancet Neurol. 2008;7(5):459-466. [Context Link]
17. Fitzgibbon DR, Loeser JD. Cancer Pain: Assessment, Diagnosis, and Management. Lippincott Williams & Wilkins; 2010. [Context Link]
18. American Cancer Society. Signs and symptoms of cancer. 2012. http://www.cancer.org/cancer/cancerbasics/signs-and-symptoms-of-cancer. [Context Link]
19. Pasero C, McCaffery M Pain Assessment and Pharmacologic Management. St. Louis: Mosby; 2011. [Context Link]
20. Wickham R. Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice. Clin J Oncol Nurs. 2007;11(3):361-376. [Context Link]
21. Stubblefield MD. Cancer rehabilitation. Semin Oncol. 2011;38(3):386-393. [Context Link]
22. Niravath P. Aromatase inhibitor-induced arthralgia: a review. Annals of Oncology. [e-pub March 6, 2013.] [Context Link]
23. Paice JA. Chronic treatment-related pain in cancer survivors. Pain. 2011;152(suppl 3):S84-S89. [Context Link]
24. Fu M, Smith J. Lymphedema management. In: Ferrell B, Coyle N, eds. Oxford Textbook of Palliative Nursing. 3rd ed. New York: Oxford University Press; 2010:341-358. [Context Link]
25. Dizon DS. Quality of life after breast cancer: survivorship and sexuality. Breast J. 2009;15(5):500-504. [Context Link]
26. Vistad I, Cvancarova M, Kristensen GB, Fossa SD. A study of chronic pelvic pain after radiotherapy in survivors of locally advanced cervical cancer. J Cancer Surviv. 2011;5(2):208-216. [Context Link]
27. Otis_Green S, Sherman R, Perez M, Baird RP. An integrated psychosocial_spiritual model for cancer pain management. Cancer Pract. 2002;10(suppl 1):S58-S65. [Context Link]
28. Gunnarsdottir S, Donovan HS, Serlin RC, Voge C, Ward S. Patient-related barriers to pain management: the Barriers Questionnaire II (BQ-II). Pain. 2002;99(3):385-396. [Context Link]
29. Pachman DR, Barton DL, Swetz KM, Loprinzi CL. Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain. J Clin Oncol. 2012;30(30):3687-3696. [Context Link]
30. Bruera E, Portenoy RK. Cancer Pain: Assessment and Management. Cambridge University Press; 2010. [Context Link]
31. Paice JA, Ferrell B. The management of cancer pain. CA Cancer J Clin. 2011;61(3):157-182. [Context Link]
32. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: adult cancer pain. 2011. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp-supportive. [Context Link]
33. Davies P, D'Arcy Y. Compact Clinical Guide to Cancer Pain Management: An Evidence-Based Approach for Nurses. Springer Publishing Company; 2013:271-300. [Context Link]
34. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med. 2003;349(20):1943-1953. [Context Link]
35. Chou R, Fanciullo GJ, Fine PG American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130. [Context Link]
36. Lavoie Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy. A randomized clinical trial. JAMA. 2013;309(13):1359-1367. [Context Link]
37. Rao RD, Michalak JC, Sloan JA, et al. Efficacy of gabapentin in the management of chemotherapy_induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 2007;110(9):2110-2118. [Context Link]
38. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med. 2009;122(suppl 10):S22-S32. [Context Link]
39. Krenzelok EP. The FDA Acetaminophen Advisory Committee Meeting-what is the future of acetaminophen in the United States? The perspective of a committee member. Clin Toxicol (Phila). 2009;47(8):784-789. [Context Link]
40. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57(8):1331-1346. [Context Link]
41. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354(7):731-739. [Context Link]
42. Hawkins C, Hanks GW. The gastroduodenal toxicity of nonsteroidal anti-inflammatory drugs: a review of the literature. J Pain Symptom Manage. 2000;20(2):140-151. [Context Link]
43. Hunt RH, Choquette D, Craig BN, et al. Approach to managing musculoskeletal pain: acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs. Can Fam Physician. 2007;53(7):1177-1184. [Context Link]
44. Zacher J, Altman R, Bellamy N, et al. Topical diclofenac and its role in pain and inflammation: an evidence-based review. Curr Med Res Opin. 2008;24(4):925-950. [Context Link]
45. McCleane G. Topical analgesics. Anesthesiol Clin. 2007;25(4):825-839. [Context Link]
46. Passik SD, Kirsh KL. Chemical coping: The clinical middle ground. In HS Smith & SD Passik (eds), Pain and Chemical Dependency. New York: Oxyford Univeristy Press; 2008:299-302. [Context Link]
47. American Cancer Society. National Cancer Survivorship Resource Center. http://www.cancer.org/treatment/survivorshipduringandaftertreatment/nationalcanc. [Context Link]
48. Nail LM. Long-term persistence of symptoms. Semin Oncol Nurs. 2001;17(4):249-254.
49. Ganz PA. Quality of care and cancer survivorship: the challenge of implementing the Institute of Medicine recommendations. J Oncol Pract. 2009;5(3):101-105. [Context Link]
50. Baehring J, Wollmann G. Neurologic sequelae of cancer therapy. In: Miller K, ed. Medical and Psychosocial Care of the Cancer Survivor. Boston, MA: Jones & Bartlett; 2010:323-339. [Context Link]
51. Wilkes G. Peripheral neuropathy related to chemotherapy. Semin Oncol Nurs. 2007;23(3):162-173.
52. Syrjala K, Martin P, Deeg J, Boeckh M. Medical and psychosocial issues in transplant survivors. Cancer Survivorship. 2007:188-214.
53. Miller K. Medical and Psychosocial Care of the Cancer Survivor. Jones & Bartlett Learning; 2010. [Context Link]
For life-long learning and continuing professional development, come to Lippincott's NursingCenter.
Update on the American Diabetes Association Standards of Medical Care
The Nurse Practitioner: The American Journal of Primary Health Care, 16August 2014
Expires: 8/31/2016 CE:3 $27.95
Pancreatic cancer: Out of the shadows
Nursing Made Incredibly Easy!, July/August 2014
Expires: 8/31/2016 CE:2 $21.95
Managing the ups and downs of ulcerative colitis
Nursing2014 , August 2014
Expires: 8/31/2016 CE:2.3 $21.95
More CE Articles
Subscribe to Recommended CE
Searching for proof: Creating and using an actionable PICO question
Nursing Management, August 2014
Free access will expire on September 15, 2014.
Sharing your nursing story
Nursing2014 , August 2014
Free access will expire on September 1, 2014.
Transradial vascular access: A growing trend
The Nurse Practitioner: The American Journal of Primary Health Care, 16August 2014
Free access will expire on September 1, 2014.
More Recommended Articles
Subscribe to Recommended Articles
Back to Top